TW200503707A - Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease - Google Patents

Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease

Info

Publication number
TW200503707A
TW200503707A TW092134949A TW92134949A TW200503707A TW 200503707 A TW200503707 A TW 200503707A TW 092134949 A TW092134949 A TW 092134949A TW 92134949 A TW92134949 A TW 92134949A TW 200503707 A TW200503707 A TW 200503707A
Authority
TW
Taiwan
Prior art keywords
alzheimer
intestinal
disease
prevention
application
Prior art date
Application number
TW092134949A
Other languages
English (en)
Chinese (zh)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert Heuer
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TW200503707A publication Critical patent/TW200503707A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
TW092134949A 2002-12-12 2003-12-11 Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease TW200503707A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
TW200503707A true TW200503707A (en) 2005-02-01

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092134949A TW200503707A (en) 2002-12-12 2003-12-11 Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease

Country Status (22)

Country Link
EP (1) EP1572174A1 (https=)
JP (1) JP2006514063A (https=)
KR (1) KR20050084250A (https=)
CN (1) CN1726016A (https=)
AR (1) AR042354A1 (https=)
AU (1) AU2003296802A1 (https=)
BR (1) BR0317280A (https=)
CA (1) CA2507945A1 (https=)
CO (1) CO5700712A2 (https=)
FR (1) FR2848452B1 (https=)
HR (1) HRP20050534A2 (https=)
MA (1) MA27500A1 (https=)
MX (1) MXPA05005556A (https=)
NO (1) NO20053341L (https=)
NZ (1) NZ540496A (https=)
PE (1) PE20040770A1 (https=)
PL (1) PL377110A1 (https=)
RS (1) RS20050420A (https=)
RU (1) RU2005121909A (https=)
TW (1) TW200503707A (https=)
WO (1) WO2004062652A1 (https=)
ZA (1) ZA200504656B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
KR101441725B1 (ko) * 2007-05-22 2014-09-18 오츠카 세이야쿠 가부시키가이샤 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) * 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
EP0572560B1 (en) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
CA2258744A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ATE320803T1 (de) * 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
MXPA05005556A (es) 2005-07-26
BR0317280A (pt) 2005-11-08
PL377110A1 (pl) 2006-01-23
PE20040770A1 (es) 2004-12-10
FR2848452B1 (fr) 2007-04-06
CN1726016A (zh) 2006-01-25
FR2848452A1 (fr) 2004-06-18
WO2004062652A1 (fr) 2004-07-29
EP1572174A1 (fr) 2005-09-14
RU2005121909A (ru) 2006-01-20
RS20050420A (sr) 2007-04-10
ZA200504656B (en) 2006-08-30
JP2006514063A (ja) 2006-04-27
AR042354A1 (es) 2005-06-15
MA27500A1 (fr) 2005-08-01
AU2003296802A1 (en) 2004-08-10
KR20050084250A (ko) 2005-08-26
CO5700712A2 (es) 2006-11-30
HRP20050534A2 (en) 2006-11-30
NO20053341D0 (no) 2005-07-08
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
CA2507945A1 (fr) 2004-07-29

Similar Documents

Publication Publication Date Title
GB0223040D0 (en) Therapeutic compounds
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
AP2004002951A0 (en) "Combination of Eplerenone and an HMG CoA Reductase Inhibitor".
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
EP1765388B8 (de) Kombinationstherapie zur vorbeugung oder behandlung der alzheimerschen erkrankung sowie set hierfür
PL377344A1 (pl) Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
PL1663185T3 (pl) Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego
MY133332A (en) Pyrrolidone derivatives as maob inhibitors
TW200509937A (en) Novel compounds and their use in therapy
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
TW200503707A (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease
AU2003290799A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MX2007006279A (es) Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
IL174536A0 (en) Therapeutic treatment
WO2001037876A3 (en) Methods of ameliorating abnormal bone states
AU2003249930A1 (en) Proteaseome inhibitors for the treatment of herpesviridae infected individuals
TW200714280A (en) Novel method of treating hyperlipidemia
WO2004080450A3 (en) Combined use of a fibrate and orlistat for the treatment of obesity
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
EP1548445A3 (en) Novel targets for obesity from fat tissue
WO2003063784A3 (en) MOLECULES THAT MODULATE GαQ ACTIVITY AND METHODS OF TREATING URINARY INCONTINENCE